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A rapid bioluminescence assay for measuring
myeloperoxidase activity in human plasma
Reece J. Goiffon1, Sara C. Martinez1 & David Piwnica-Worms1,2

Myeloperoxidase (MPO) is a circulating cardiovascular disease (CVD) biomarker used to
estimate clinical risk and patient prognosis. Current enzyme-linked immunosorbent assays
(ELISA) for MPO concentration are costly and time-intensive. Here we report a novel
bioluminescence assay, designated MPO activity on a polymer surface (MAPS), for
measuring MPO activity in human plasma samples using the bioluminescent substrate L-012.
The method delivers a result in under an hour and is resistant to confounding effects from
endogenous MPO inhibitors. In a pilot clinical study, we compared MAPS and two clinical
ELISAs using 72 plasma samples from cardiac catheterization patients. Results from parallel
MAPS and ELISAs were concordant within 2±11 mg l  1 MPO with similar uncertainty and
reproducibility. Results between parallel MAPS and ELISA were in better agreement than
those between independent ELISAs. MAPS may provide an inexpensive and rapid assay for
determining MPO activity in plasma samples from patients with CVD or potentially other
immune and inﬂammatory disorders.
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has also been used to measure ROS in vivo and in vitro with
enhanced luminescence and sensitivity (Fig. 1a)15–17. Intracellular
MPO concentrations at inﬂammation loci are high enough to
oxidize bioluminescent probes for real-time, whole-animal
imaging with charge-coupled device cameras, but circulating
MPO is normally inhibited by proteins such as ceruloplasmin and
antioxidants such as ascorbic acid18,19. Here we describe a new
technique to assay MPO activity from whole plasma samples after
eliminating inhibitors without requiring immunosorbent reagents
or complex sample processing. This activity assay is simple,
cost-effective and more sensitive than current ELISA techniques.
Results
MPO oxidizes L-012 by chlorination and bromination. Full
biochemical characterization of the MPO reaction under varied
conditions was ﬁrst pursued to optimize bioluminescence from
the novel MPO activity assay. Although substrate interactions
with MPO are far more complex than kinetics described by the
Michaelis–Menten equation (Fig. 1b), NaCl and NaBr at relevant
concentrations ﬁt the model as classic substrates in terms of their
effects on MPO-induced bioluminescence of L-012 (Fig. 2).
In acidic citrate buffer, MPO bioluminescence plateaus near
physiological extracellular NaCl concentrations with a Km ¼ 17
(10–23) mM. NaBr is a more efﬁcient halogenation substrate with
B10-fold higher bioluminescence and afﬁnity, Km ¼ 2.3
(1.7–2.9) mM. Contrary to literature reports, NaI and NaSCN did
not generate ROS suitable for L-012 oxidation under these
reaction conditions.
Antioxidants in plasma inhibit MPO bioluminescence. Fresh
plasma from healthy volunteers added to pure MPO inhibited
bioluminescence with an IC50 ¼ 28 (21–35) p.p.m. (Fig. 3a).
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Figure 1 | Biochemistry of MPO/L-012 bioluminescence. (a) Reaction of
L-012 with ROS produced by MPO. Solution conditions can be optimized to
effectively eliminate H2O2 chemiluminescence, rendering L-012 a
bioluminescent reporter speciﬁc for MPO activity in living systems.
(b) MPO has complex redox kinetics involving H2O2 and various electron
carriers. Rapid halogenation (blue) is required to generate hypohalous
acids. H2O2 (red) is both a halogenation substrate and inhibitor: excess
H2O2 shifts MPO from halogenation with halide X  and H2O2 into slower
peroxidation cycles with electron donor AH2. Scheme adapted from Malle
et al.57
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therosclerotic cardiovascular disease (CVD) is the leading
cause of morbidity, mortality and health care costs in the
developed world, a distinction that is projected to apply
globally within the next decade1,2. Many metabolic and
haemodynamic factors inﬂuence atherosclerosis progression,
deﬁned by arterial wall inﬂammation3. Atherosclerosis often
ﬁrst presents as a major adverse cardiovascular event (MACE),
suggesting that identifying high-risk patients with subclinical
disease before the ﬁrst MACE is a vital prevention strategy4.
Many proposed biomarkers for risk stratiﬁcation target the
inﬂammation underlying plaque development and instability5.
The heme-containing antimicrobial enzyme myeloperoxidase
(MPO) is one of these biomarkers.
MPO constitutes 5% of neutrophil dry weight and is
concentrated in primary granules6. On neutrophil activation,
these granules fuse to the phagosomal or cell membrane to
oxidize biomolecules with hypochlorous acid produced by MPO7.
Reactive oxygen species (ROS) generated by MPO can oxidize
apolipoproteins, disrupt endothelial function and accumulate in
the shoulder regions of plaques, suggesting a possible role in
atherogenesis8,9.
Previous studies reviewed elsewhere have shown that circulating MPO levels correlate with measures of CVD severity and
predict short- and long-term patient outcomes10,11. Plasma
MPO concentration is usually measured by enzyme-linked
immunosorbent assay (ELISA)11, which is costly, time-intensive
and typically uses ROS generated by immunoconjugate
horseradish peroxidase (HRP) instead of directly measuring
MPO-derived ROS. Historically, attempts to measure MPO by its
intrinsic activity show that this requires either immunologic
puriﬁcation or a chemically simple source12,13.
We have previously shown that MPO activity can be imaged
directly in vivo with luminol, a chemiluminescent compound
oxidized by hypochlorous acid14. L-012 is a luminol analogue that

NaSCN (M)

Figure 2 | Halogenation substrates for MPO bioluminescence. (a) As
suggested by the literature, MPO utilizes physiological concentrations of
NaCl, Km ¼ 17 (10–23) mM, less effectively than (b) NaBr, Km ¼ 2.3
(1.7–2.9) mM. Although reported as even more efﬁcient substrates for
MPO, (c) I  and (d) SCN  do not produce similar MPO-mediated
bioluminescence with L-012 under these reaction conditions.
Representative data (n ¼ 4) are shown as mean±s.d.. Regression 95%
conﬁdence bands are shown in grey when applicable. MPO is labelled
with ﬁnal imaging concentration.
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Figure 3 | Plasma inhibits MPO-mediated bioluminescence.
(a) Representative plasma ﬁltrate titration curves in the presence of
500 ng l  1 MPO imaged with L-012 and H2O2. Whole plasma had a broad
inhibitory concentration range with an IC50 ¼ 28 (21–35) p.p.m. v/v.
Removing plasma components 4100 kDa narrowed the inhibitory
concentration range, but only modestly increased the IC50 to 120
(110–140) p.p.m. Plasma components o5 kDa were not signiﬁcantly
different from o100 kDa in terms of inhibiting MPO bioluminescence
(nonlinear regression P ¼ 0.21). (b) Endogenous antioxidant titration curves
equivalent to plasma with 20 mg l  1 MPO imaged at a 0.4% v/v dilution.
Ascorbic acid inhibition IC50 ¼ 36 (31–41) nM, uric acid IC50 ¼ 150
(120–180) nM in the presence of 80 ng l  1 MPO. The lower black bar spans
the physiological plasma reference range of ascorbic acid adjusted by the
same dilution factor; the upper black bars span the male and female uric
acid reference ranges20. Representative data (n ¼ 4) are mean±s.d.
Regression 95% conﬁdence bands shown in grey.

Removing proteins 4100 kDa via ultraﬁltration narrowed the
inhibitory concentration range and increased the IC50 to 120
(110–140) p.p.m. Further ﬁltration to remove plasma components
45 kDa had no signiﬁcant effect on IC50 (nonlinear regression
P ¼ 0.21). Potent inhibition of MPO bioluminescence by endogenous plasma components o5 kDa suggests that MPO is predominantly inhibited by small-molecule antioxidants compared
with the contribution from proteins such as ceruloplasmin in
these reaction conditions.
Two potential endogenous inhibitors, ascorbic and uric acid,
were titrated in the presence of MPO in solution at physiological
ratios to directly quantify their antioxidant effects (Fig. 3b).
Ascorbic acid inhibited MPO (80 ng l  1) with an IC50 ¼ 36
(31–41) nM. These concentrations recapitulated pre-dilution
human plasma containing 9 mM ascorbic acid (physiological
reference range 34–91 mM)20 and 20 mg l  1 MPO. As predilution ascorbic acid concentrations neared the high reference
range cutoff, MPO signal was fully quenched. Uric acid also
inhibited MPO, but showed a higher IC50 ¼ 150 (120–180) nM.
These data indicated that a direct plasma MPO activity assay
would require elimination of antioxidants by dilution or selective
removal. Unfortunately, dilution strategies were unsuccessful as
plasma required dilution beyond the MPO detection threshold to
effectively overcome antioxidant inhibition.
MPO activity on a polymer surface (MAPS) assay. A strategy for
assaying MPO from human plasma evolved from the biochemical
analysis. Our initial ﬁndings indicated that MPO must ﬁrst be
isolated from native plasma inhibitors before its activity can be
assayed with L-012 bioluminescence. This was accomplished by
nonspeciﬁc adsorption of MPO onto a solid surface, which was
then washed free of antioxidants. Pure MPO did not adsorb onto
tissue culture-treated polystyrene alone, but strongly adsorbed
when co-incubated with dilute human plasma (data not shown).
Reconstituted bovine plasma (RBP) also allowed MPO adsorption
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Figure 4 | RBP facilitates MPO binding without contributing to
bioluminescence. (a) RBP supplemented with MPO and titrated with
protamine sulfate before loading onto a MAPS assay plate. MPO detection
from supplemented RBP is inhibited with IC50 ¼ 590 (560–620) mg l  1
protamine sulfate. Native RBP is not similarly affected by increasing
concentrations of protamine sulfate and remains at baseline, demonstrating
the lack of intrinsic MPO detectable by MAPS assay. All samples converge
to native RBP at high concentrations of protamine sulfate. Regression
conﬁdence bands are shown in grey. (b) Titration curves of 4-aminobenzoic
hydrazide (4-ABH) in MAPS imaging buffer on a plate loaded with RBP
supplemented with human MPO. 4-ABH inhibited MAPS bioluminescence
with an IC50 ¼ 25 (22–28) nM. Native RBP was not inhibited. Data are
plotted as mean±s.d. (n ¼ 4). MPO concentrations represent whole RBP,
pre-dilution.

and is preferable to human plasma in terms of availability and
reduced biohazard potential.
Native RBP contributed negligible signal to the MAPS assay as
demonstrated by two methods. First, competitively blocking
cationic protein adsorption, including MPO, eliminated any
MAPS bioluminescence. For example, protamine sulfate completely inhibited detectable MAPS from RBP supplemented with
human MPO with an IC50 ¼ 590 (560–620) mg l  1 (Fig. 4a), but
had no effect on native RBP signal, which remained at the
baseline across the range of protamine concentrations as would
be expected from plasma without intrinsic MPO activity. This
ﬁnding was repeated with two different lots of RBP obtained
independently. Second, 4-aminobenzoic hydrazide, a speciﬁc
MPO antagonist21, titrated into the MAPS imaging buffer
similarly inhibited bioluminescence from MPO-supplemented
RBP with an IC50 ¼ 25 (22–28) nM (Fig. 4b). 4-aminobenzoic
hydrazide did not have this effect on native RBP. This also
provided direct evidence that L-012 bioluminescence in the
MAPS assay requires active MPO.
Varying pre-assay plasma ascorbic acid concentrations had
minimal effect on MAPS bioluminescence, demonstrating that
the protocol mitigated the previously observed effects of smallmolecule plasma MPO inhibitors (Fig. 5a). However, other
speciﬁc MPO inhibitors, most notably ceruloplasmin, are known
to adsorb onto treated polystyrene22. (NH4)2SO4 added to the
MAPS imaging solution to disrupt non-covalent interactions
between MPO and macromolecular inhibitors resulted in an
B10-fold increase in bioluminescence (Fig. 5b). This enhancing
effect was modest with MPO assayed in solution format with
diluted plasma containing native antioxidants, and altogether
absent with MPO in pure buffer (Fig. 5c,d). Furthermore, Na2SO4
did not enhance MAPS bioluminescence at the same
concentrations, conﬁrming the requirement for NH4þ ions
(Fig. 5e). Thus, the ﬁnal MAPS assay protocol included
(NH4)2SO4 in the imaging buffer to eliminate potential adverse
effects of coadsorbed plasma inhibitors on MPO activity.
Using the MAPS technique, RBP supplemented with human
MPO produced near-linear titration curves with high reproducibility (Fig. 6a,b). The MPO concentrations were chosen to cover
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buffer is not enhanced by (NH4)2SO4 in the same manner as seen with MAPS. MPO concentrations represent post-dilution into the microtitre plate wells.
(e) RBP supplemented with human MPO and imaged with varying Na2SO4, which has a mild inhibitory effect. Bioluminescence enhancement seen with
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Clinical study population characteristics. We next applied the
MAPS assay in a pilot clinical trial of human samples. The clinical
characteristics of the patient cohort as they presented prior to
elective cardiac catheterization are shown in Table 1. We
recruited patients with diverse demographic and clinical proﬁles.
As expected from the selection criteria, average plasma MPO
concentration in this cohort was slightly lower than literature
reports on higher-risk patients, such as those presenting with
acute coronary syndrome (ACS). Of note, 17 patients had
received i.v. heparin prior to sampling. We previously observed
that plasma collected from heparinized vacuum tubes did not
have strong MAPS bioluminescence, indicating that heparin at
high concentrations may block MPO adsorption by a mechanism
similar to protamine sulfate. Despite this possibility, samples
from patients treated with heparin had detectable MAPS
bioluminescence and were included in this analysis.
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Figure 6 | MAPS assay with RBP carrier. (a) Example standard solution
image and (b) calibration curve constructed with puriﬁed human MPO
diluted into RBP for MAPS assay. Data are plotted as mean±s.d. (n ¼ 3).
Triplicate 95% prediction band shown in grey. (c) MAPS assay results using
human plasma from healthy volunteers supplemented with puriﬁed human
MPO to simulate samples covering the range of a commercial ELISA kit.
Data are plotted as regressed value±95% conﬁdence intervals.
Dashed line represents 1:1 agreement between supplemented MPO and
RBP-regressed MPO.

the range suggested by commercial kit manufactureres and were
skewed to improve resolution near literature prognostic thresholds (typically 30–70 mg l  1). MAPS was precise by weighted least
squares (WLS) regression analysis (R240.999) and used plasma
diluted 10-fold beyond requirements for ELISA. Furthermore, to
simulate clinical samples, human plasma from healthy volunteers
was then supplemented with incremental MPO concentrations
and calibrated against MPO standards in RBP (Fig. 6c). Results
from this simulated MAPS assay consistently agreed with the
known MPO values within 95% conﬁdence limits.
4

Comparative measurement of human plasma MPO. Seventytwo plasma samples were analyzed by MAPS and an ELISA kit
protocol modiﬁed to minimize procedural variance and allow
direct, quantitative comparison (that is, assays ‘in parallel’).
Blocks of 24 plasma samples and 8 MPO standard curve solutions
spanning the concentration range recommended by the kit
manufacturer were analyzed in triplicate. In addition, 67 plasma
samples with adequate volume were also analyzed independently
by the Cleveland HeartLab (CHL), LLC (Cleveland, OH, USA),
which offers Food and Drug Administration (FDA)-approved,
ELISA-based clinical MPO assay services. Differences in protocol
and reported units limit quantitative comparison between the
CHL results and those from either parallel assay.
The WLS calibration curve parameters consistently differed
between the two methods: both ELISA curves were moderately
concave owing to the saturable nature of absorbance measurements, while MAPS curves were linear or marginally convex
(Fig. 7a). Concavity reduces overall assay resolution, as evident by
the statistically signiﬁcant difference in the computed limits of
detection: 6.0 (5.3–6.6) mg l  1 for MAPS and 7.4 (6.7–8.1) mg l  1
for the parallel ELISA (generalized linear regression P ¼ 0.002).
MPO determined by the two parallel methods was highly
correlated (Pearson r ¼ 0.97, Fig. 7b and Table 2). The global
disagreement between the two assays was not signiﬁcant
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Table 1 | Clinical data from plasma donors.
N
Age (years)
Female:Male
Eur:Afr:Asn:Hisp
BMI (kg m  2)
Family CVD history
Current smoker
Hypertension
Diabetes mellitus
Known CAD
Prior PCI
Prior CABG
Total cholesterol (mg dl  1)
LDL (mg dl  1)
HDL (mg dl  1)
Aspirin
b-blockers
Statins
P2Y12 inhibitors
Heparin
p-ELISA MPO (mg l  1)
MAPS MPO (mg l  1)
CHL MPO (pM)

72*
63±14
35:37
54:15:2:1
29±7
34 (6)
39 (1)
58
23
36
21
8
172±48
98±37
46±22
49
41 (1)
39
21
17
20±16
14±13
330±140

Afr, African; Asn, Asian; BMI, body mass index; CABG, coronary artery bypass graft; CAD,
coronary artery disease; CVD, cardiovascular disease; ELISA, enzyme-linked immunosorbent
assay; Eur, European; FDA, Food and Drug Administration; Hisp, Hispanic; MAPS, MPO activity
on a polymer surface; MPO, myeloperoxidase; PCI, percutaneous coronary intervention.
Mean±s.d. are given when applicable. Parentheses indicate absent patient data. p-ELISA refers
to the parallel-protocol ELISAs modiﬁed to approximate the MAPS protocol as closely as
possible and eliminate systematic error. CHL is the FDA-approved MPO assay performed
independently by the Cleveland HeartLab.
*CHL N ¼ 67 due to limited sample volume.

(matched pair generalized linear regression P ¼ 0.46). Disagreement that did exist was largely due to the combination of both
data set uncertainties. To adjust for this, we weighted each plasma
sample by the inverse product of assay uncertainty, resulting in
even less deviation from agreement (weighted generalized linear
regression P ¼ 0.61).
Although parallel MAPS and ELISA agreed over this entire
cohort, individual plasma measurements deviated with 95%
limits of agreement of 2±11 mg l  1 MPO (Fig. 7c). Uncertainty,
which accounts for variance in both the calibration curve and
individual plasma samples, was also consistently distributed
between the two assays: ELISA uncertainty with 95% coverage
was  2±12 mg l  1 compared with that of MAPS.
MAPS and the CHL assay were also well-correlated
(uncertainty-weighted and unweighted correlation r ¼ 0.90 and
0.86, respectively, Fig. 7d and Table 2). Although precise
quantiﬁcation of the disagreement is limited by the difference
in calibration standards, the agreement of both parallel assays
with the CHL results can be compared by using an approximate
MPO molecular weight of 150,000 kDa. The overall disagreement
of both the MAPS assay and parallel ELISA protocol with the
CHL results were strongly correlated (r ¼ 0.99) and did not
signiﬁcantly vary with MPO as paired data across patients
(generalized linear regression P ¼ 0.20, Fig. 7e). Of note, this
demonstrates that varying protocol details for mechanistically
similar assays, in this case two ELISAs performed at different
sites, is more detrimental to reproducibility than is the
comparatively large operational difference between how the
measured quantity is produced in MAPS versus ELISA.
MAPS assay reproducibility. We performed additional, independent replications of the MAPS assay with all 72 patient
samples on 3 separate days. By combining the inter- and
intra-assay replication variances from these and the initial

replicates, we were able to calculate absolute replication variability
for each sample (Fig. 8a). The median and 95th percentile
replication variability scores were 0.67 mg l  1 MPO and
5.8 mg l  1 MPO, respectively. Variability was proportional to
mean MPO by a ratio of 0.12 (0.11–0.13). By normalizing these
values to the replicate means, we computed a more robust version
of the coefﬁcient of variation (Fig. 8b). This also makes the difference between two sample groups—those with homoscedastic
and heteroscedastic variability—more apparent. Even when
including the heteroscedastic samples, the median coefﬁcient of
variability was 8.6% with 95th percentile coverage by 27%.
Discussion
MPO is an inﬂammation biomarker that has been shown to be
independently associated with acute and chronic risk of MACEs
in patients with established CVD, presenting with ACS, or
undergoing diagnostic cardiac catheterization10,11,23. Serial
measurements are predictive of acute progression from ACS to
a MACE in patients with negative troponin I levels24. It has also
been shown to predict CVD development in otherwise healthy
individuals25. In this study, we show that human plasma MPO
can be assayed by a conceptually new method, MAPS, as an
alternative to ELISA. The MAPS assay method is advantageous to
ELISA in terms of cost, time, complexity and sample
consumption. Increasing the clinical stability and accessibility of
an MPO assay allows for investigation of CVD risk stratiﬁcation,
outcomes and management.
The measured quantity of our MAPS assay fundamentally
differs from that of ELISA: instead of using the activity of
immunoconjugated HRP to measure the mass concentration of
MPO, MAPS directly measures MPO enzyme activity. Both types
of measurement are hypothetically subject to confounding
factors. The MAPS assay assumes equivalent enzyme activity
compared with the reference standard and could underestimate
MPO concentration should a patient have hypomorphic MPO.
Both our observations and those in the literature suggest that the
assumption of constant activity is reasonable26.
Unintuitively, ELISA has potential for the same problem: MPO
and HRP can both catalyze the reaction responsible for the
change in 450 nm absorbance. In addition, ELISA also requires
the assumption of antigenic homogeneity. Thus DAbs450 is
not a linear function of MPO concentration, but rather a
combination of MPO activity, HRP activity and the combined
afﬁnity of two different antibodies for sample MPO. Although
this study did not identify any patients with highly discrepant
results between the methods, we cannot assume that mutations
and other confounding factors would have no effect in a much
larger population.
As a general technique, ELISA is considered to be robust and
reliable. Disagreement in ELISA results can come from external
sources (such as operator technique, sample handling or random
variation) or intrinsic sources (such as antibody afﬁnities, epitope
frequency or nonspeciﬁc effects of reagents and buffers on the
analyte). Both the CHL and bench-top kit ELISAs are wellvalidated and thus the intrinsic sources of discrepancy are
minimal compared with the conceptual intrinsic differences
between ELISA and MAPS. From this, we initially hypothesized
that the two ELISAs would correlate more with each other than
either would with MAPS. We tested this hypothesis by
minimizing the extrinsic differences between an ELISA and the
MAPS assay by performing them in parallel. We instead found
that the CHL-ELISA, which was automated and performed by the
CHL unmodiﬁed internal protocol, agreed less with our ELISA
than did our parallel-protocol MAPS assay. The overall distribution of data shows that the CHL assay has an elevated baseline
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Figure 7 | MAPS and ELISA with clinical plasma samples. (a) Three
calibration curves with triplicate prediction bands. The mean limit of
detection for MAPS was signiﬁcantly lower than for ELISA, 6.0 (5.3–6.6)
and 7.4 (6.7–8.1) mg l  1, respectively (generalized linear regression
P ¼ 0.002). (b) Regressed plasma MPO from 72 clinical plasma samples.
Error bars show combined uncertainty from calibration curves and interreplicate variance by WLS regression. The assays are not signiﬁcantly
different from perfect agreement (dashed line) by either unweighted
(P ¼ 0.46) or uncertainty-weighted (P ¼ 0.61) matched pair linear
regression. (c) Discrepancy (ELISA–MAPS) of both MPO result and
uncertainty. Dashed lines are means and 95% coverage limits. The
assays agreed within 2±11 mg l  1 MPO and varied in uncertainty by
 2±12 mg l  1 MPO. (d) Results of the MAPS and CHL assays from 67
clinical plasma samples. Standardization unit disagreement limits analysis
to correlation calculated, respectively, as Pearson r ¼ 0.90 and 0.86 when
weighted and unweighted by combined uncertainty. (e) CHL results differ
similarly from MAPS and protocol-matched ELISA. CHL-ELISA and
CHL-MAPS disagreement is not signiﬁcantly different across the cohort
(generalized linear regression P ¼ 0.20). CHL data were converted to
microgram per litre by an estimate for MPO molecular weight for direct
comparison.

and greater relative uncertainty in the low-end of MPO
concentrations compared with MAPS and the parallel ELISA.
In patient samples exceeding B30 mg l  1, the CHL and MAPS
data agree linearly within uncertainty limits. Only one patient was
an obvious outlier, but this sample produced highly variable data
from the CHL assay and thus cannot be conﬁrmed as a true
outlier with conﬁdence.
6

Some possible sources of this variation include the time passed
between the parallel assays and the CHL measurements, effects of
sample shipment to the control lab, standard curve concentration
intervals and execution by automated ﬂuid handlers versus hand
pipetting. That these unavoidable extrinsic sources of variation
had a larger effect than the conceptual difference between the
parallel ELISA and the MAPS assay demonstrates how suitable
MAPS is as a substitution for ELISA. Our data suggest that MPO
activity measured with MAPS and concentration as measured by
ELISA are sufﬁciently correlated in the range of plasma MPO
expected from clinical samples.
Although similar to ELISA in terms of results and reproducibility, we propose that the MAPS assay has many practical
advantages. Most obvious is the difference in cost: MAPS
does not require antibodies or assay-speciﬁc labware. We estimate
the cost per-patient as o5% than that of ELISA. In addition,
ELISA requires numerous reagent exchanges and incubations
spanning many hours. The MAPS assay required only one
incubation for which we arbitrarily chose 30 min for consistency.
Further pilot data suggested that this can be shortened to
10 min with comparable MPO resolution. MAPS also appears
to be more linear than ELISA, in part because luminescence
is less saturable than absorbance. Higher sensitivity also
allows MAPS to be measured from plasma samples diluted
10-fold from that required by standard ELISA, further extending
the dynamic range in addition to requiring far less sample
material.
There may be limitations to the MAPS method. At this time,
the plasma components required for coadsorption are unknown.
We unsuccessfully tested many pure carrier proteins, but only
whole RBP gave reproducible, linear responses to MPO. We also
found that heparinized phlebotomy tubes reduced MPO adsorption. Not only does this raise concern over i.v. heparin potentially
interfering with the assay, but also suggests that the effects of
other plasma components need to be further investigated. There
was no statistically signiﬁcant trend among the samples from
patients treated with i.v. heparin for lower MAPS results
compared with ELISA, but our study was neither designed nor
powered to investigate this.
Although most literature investigating the clinical usefulness of
MPO shows positive results, there are also examples of negative
studies. When considering conﬂicting results, it is important to
note the effect of protocol on MPO measurements. Previous work
shows that MPO can be inﬂuenced by processing time,
temperature and anticoagulants27–29. In studies of patients
presenting with chest pain or proven myocardial infarction,
systemic administration of heparins is another potentially
confounding factor30,31. Studies with weak or negative results
often lack detailed descriptions of protocols used to collect
samples32–34, used heparin-treated tubes35 or measured MPO
from serum36. In a notable negative study with MPO measured in
EDTA-treated samples collected from heparin-naı̈ve patients37,
MPO concentration was log-transformed due to its skewed
distribution; not only is such a transformation unnecessary, but it
can obfuscate the true underlying relationships between
covariates and outcomes38. These issues in methodology and
analysis underscore the need for more investigation of MPO and
its clinical utility. Our pilot study demonstrates the fundamental
feasibility of the MAPS assay in a clinical setting, which we hope
encourages such research in the near future.
Although we used an advanced imaging system in developing
this assay, MAPS can be measured with common laboratory
equipment. We successfully performed MAPS assays using a
standard digital camera intended to photograph gel electrophoresis bands. Microtiter plate luminometers also open the assay
to high-throughput automation. Because this assay only requires
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Table 2 | Pearson correlations between clinical MPO assay
results.
MAPS
—
0.960
0.895

MAPS
p-ELISA
CHL

p-ELISA
0.969
—
0.911

CHL
0.860
0.893
—

ELISA, enzyme-linked immunosorbent assay; MAPS, MPO activity on a polymer surface; MPO,
myeloperoxidase; p-ELISA, parallel-protocol ELISA.
Upper right values are unweighted, pairwise correlations. Lower left values were obtained by
weighting patient samples by the inverse product of uncertainties from each correlated pair of
assays.
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Figure 8 | MAPS reproducibility. MAPS assays independently replicated
four times on 72 clinical plasma samples. Dashed lines show median and
one-sided 95th percentile values. Computation details are provided in
online methods. (a) Absolute replication variability quantiﬁed by
accounting for both intra- and inter-replicate uncertainty. Median variability
was 0.67 mg l  1 MPO, and 95% of samples were reproducible within
5.8 mg l  1 MPO. Variability was scaled with mean MPO by a factor of 0.12
(0.11–0.13). Dashed lines show mean and two-sided 95% coverage
variability estimates. (b) Relative replication variability by normalization to
variance-weighted replicate mean MPO. Median coefﬁcient of variability
was 8.6% with an upper 95th percentile threshold of 27%. Dashed lines
show median and one-sided 95th percentile estimate.

a hydrophilic polystyrene surface, the MAPS assay is amenable to
a dipstick platform similar to blood glucose meters.
We have developed the assay in the context of CVD, but there
are other important clinical scenarios that could beneﬁt from
rapid MPO measurement to assess inﬂammation and immune
response. A growing number of studies have suggested prognostic
value of MPO in the setting of cancer. MPO concentration was
shown to differentiate patients with hepatocellular carcinoma
from those with chronic hepatitis or severe cirrhosis in the
context of hepatitis C39. MPO has been shown to be elevated in
plasma from patients with glioblastoma multiforme and
numerous gynaecological cancers; bile MPO has also been
used to differentiate benign choledochal strictures from
cholangiocarcinoma40–42. In addition, research suggests that
neutrophils laden with MPO inﬁltrating colorectal cancer may
have a role in the anti-tumor immune response43,44.
Cardiotoxicity from chemotherapy is also predicted by MPO
levels in patients with breast cancer45. The MAPS assay has
potential uses outside of oncology as well. Serial MPO levels made
possible by a rapid, cost-effective assay could improve detection
of post-transplant graft rejection as MPO rises in patients
rejecting heart and liver allografts46,47. If developed onto a more
rapid or portable platform, MPO activity may also be useful in
diagnosing early wound infections, urinary tract infections and
advanced progression of septic shock in the acute critical care
setting48–50.

In conclusion, we have developed a facile MPO activity assay
applicable to clinical plasma samples as an alternative to ELISA.
The MAPS assay has many practical advantages including a
410-fold reduction in cost, sample material consumption and
labour requirement. Importantly, we found the MAPS assay to be
comparable to ELISA in results, uncertainty and reproducibility
in a test with 72 cardiac catheterization patient samples.
Methods
Materials. L-012 (product no. 120-04891) was supplied by Wako Chemicals USA
(Richmond, VA, USA). Human MPO ELISA kits (product no. ADI-900-115) were
supplied by Enzo Life Sciences (Farmingdale, NY, USA). Puriﬁed human MPO
(product no. 475911) was supplied by EMD Millipore/Calbiochem (Darmstadt,
Germany). Bovine plasma (product no. P4639) and all other reagents were supplied
by Sigma-Aldrich (St Louis, MO, USA). Bioluminescence readings were obtained
with the Stanford Photonics ONYX/M imaging system (Palo Alto, CA, USA). All
bioluminescence experiments were performed in Corning black-walled, 96-well
microtitre plates made from tissue culture-treated polystyrene (product no. 3603).
Human plasma samples. Plasma for assay development. Blood was drawn from
the cephalic vein of volunteers undergoing elective coronary catheterization
(37 men and 38 women, age range ¼ 30–89 with mean ¼ 63, see Table 1 for other
characteristics) into K2EDTA vacuum tubes for immediate preparation. Plasma
was isolated by two-stage centrifugation at 4 °C: 1,000g in the collection tubes for
15 min followed by 14,000g in microcentrifuge tubes for 10 min. Clinical plasma
samples: cardiac patients undergoing elective catheterization were asked to allow
collection of B10 ml of blood by a physician after successful and uncomplicated
arterial cannulation. Blood was transported on ice in K2EDTA vacuum tubes for
plasma collection via centrifugation in the same manner described above. Plasma
was stored at  80 °C and thawed on ice before use. Samples sent to the CHL had
no attached personal information and were identiﬁed only by randomly generated
demographics. The Institutional Review Board at Washington University in
St Louis approved these study protocols. All participants provided written and
informed consent at enrolment.
Solutions. Stock solutions listed below were prepared from concentrated
individual components and sterilized by microﬁltration into 50 ml conical tubes.
Additional solution components are described by experiment.
Cit6: 3.1 mM citric acid, 21.9 mM trisodium citrate
PS6.5: 130 mM NaCl, 6.28 mM Na2HPO4, 18.7 mM NaH2PO4
MPO dilution buffer: buffer PS6.5 with 200 p.p.m. v/v Tween20
MAPS loading buffer: buffer PS6.5 with 50 p.p.m. v/v Tween20
MAPS imaging solution: buffer Cit6 with 20 mM NaBr, 200 mM (NH4)2SO4,
100 p.p.m. v/v Tween20, 50 mM L-012 and 100 mM hydrogen peroxide (H2O2)
Bioluminescence imaging. All images were acquired with the ONYX/M imaging
system with a XR/MEGA-10Z camera at 55 frames per second with no optical
ﬁlter. Images were integrated for 10 s to prevent camera saturation and compiled
into 1 min exposures for quantiﬁcation with the Fiji distribution of ImageJ analysis
software51. Optical vignetting was mathematically corrected by the standard
irradiance equation calibrated to the imaging system prior to quantiﬁcation52.
All bioluminescence data are presented in dimensionless intensity units and are
uniformly scaled throughout to allow direct comparison between experiments.
MAPS assay with RBP. All volumes were added by reverse pipetting to minimize
variance from solution viscosity. Puriﬁed human MPO standards were prepared at
full concentrations via serial dilution into MPO dilution buffer. One 1.2 ml capacity
polypropylene cluster tube for every sample was ﬁlled with 500 ml MAPS loading
buffer, each of which then received 2 ml of a plasma sample. Assay standards were
similarly prepared by ﬁlling cluster tubes with 500 ml MAPS loading buffer, adding
2 ml of a standard MPO solution and ﬁnally adding 2 ml whole RBP. All tubes were
capped tightly and thoroughly mixed on a vortex mixer. Samples were then loaded
into microtiter plate wells as 100 ml volumes if done in triplicate (for example,
Figs 6b,7 and 8) or as 75 ml if done in quadruplicate (for example, Fig. 5a,b) based
on pipette constraints. The microtiter plate was covered and shaken for 30 min at
1,000 r.p.m.. Each well was vacuum-aspirated dry without contacting the well
surface and washed three times with MAPS loading buffer: twice with 150 ml then
once with 300 ml. Fresh MAPS imaging solution was prepared with L-012 and
H2O2 was added immediately before use. Each well received 75 ml imaging solution
and the plate was brieﬂy shaken up to 1,000 r.p.m. and imaged immediately.
Data were quantiﬁed at the 5-min time-point.
L-012 and MPO halogenation. All solutions were made in buffer Cit6. Reactions
were set up adding 75 ml buffered halide to 50 ml of either MPO or buffer in
microtiter plate wells. Thiocyanate, known as a ‘pseudohalide’ due to its chemical
similarity to true halides, was analyzed in the same manner. Reactions were
initiated by adding 150 ml buffered imaging solution with ﬁnal concentrations of
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100 mM H2O2 and 30 mM L-012. NaCl and NaBr titration curves were ﬁt to the
Michaelis–Menten equation.
MPO inhibition by plasma. Fresh plasma from a healthy donor was diluted to
0.5% in buffer Cit6 with 10 mM NaBr. Dilutions were ﬁltered by centrifugation in
Corning Spin-X UF concentrators with 100 and 5 kDa cutoffs (product numbers
431486 and 431482) spun for 60 min at 4,000 g and 4 °C. Diluted whole plasma was
prepared the same way and stored at 4 °C for the duration of centrifugation to
control for temperature effects. Serial dilutions of each ﬁltrate were made with ﬁnal
concentrations 10 mM NaBr, 50 mM L-012 and 500 ng l  1 MPO in the same
buffer. Bioluminescence was initiated by adding 75 ml of these solutions to a plate
arrayed with 10 ml buffered H2O2, ﬁnal concentration 50 mM. Plates were shaken
brieﬂy up to 1,000 r.p.m. and imaged. Inhibition curves were ﬁt to the equation
S¼
1þ

Smax

H

From these weighted means, a term ^
d2 describing the variance of replication was
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MPO inhibition by plasma antioxidants. Serial dilutions of ascorbic acid were
made in buffer Cit6 with ﬁnal concentrations 30 mM L-012, 80 ng l  1 MPO and
200 p.p.m. Tween20. Bioluminescence was initiated by adding 75 ml of each antioxidant titration solution to 75 ml buffered H2O2, ﬁnal concentration 100 mM.
These concentrations of MPO and antioxidants were chosen to represent plasma
from a healthy individual with 20 mg l  1 MPO diluted to 0.4% (ref. 20). Inhibition
was modelled with a modiﬁed version of equation (1) that has a term for a nonzero asymptotic minimum:
Smax  Smin
S ¼ Smin þ

H

1 þ ½antioxidant
IC50
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Statistical analysis. All statistical analyses were performed with IBM SPSS
Statistics 21 (IBM Corp., Armonk, NY, USA). Presented data are representative
of three independent replications unless otherwise noted. Regression and
measurement means are presented with 95% conﬁdence intervals in parentheses
throughout the text. Nonlinear regression conﬁdence bands were calculated using a
modiﬁed delta method with values of the gradient function estimated by the SPSS
nonlinear regression algorithm53.
Calibration conﬁdence and prediction bands (see Figs 6b and 7a) for ELISA and
MAPS were computed using a WLS regression algorithm adapted from previous
literature54,55. Calibration solutions were weighted by the inverse of the variance of
the intra-experiment replicates. Variances for the continuous calibration bands
were modelled as a function of measurement mean in the calibration solutions,
^std . Linear or quadratic calibration models were chosen by the algorithm
s2Ystd / Y
using the F-ratio test. Plotted prediction bands were constructed using the
assumption of triplicate measurements from a given unknown sample. MAPS
and ELISA were analyzed identically from experiments run with triplicate wells.
MAPS-independent replications were not combined in comparison against the
single ELISA to keep from artiﬁcially reducing MAPS result uncertainty. DMPO
was calculated as MPOELISA—MPOMAPS and Duncertainty is the analogous
difference in 95% conﬁdence interval magnitude.
MAPS reproducibility was calculated with a method adapted from published
techniques56. Each plasma sample MAPS replicate i (out of k total) was ﬁrst
weighted by the inverse of its estimate variance as determined by the WLS
conﬁdence interval.
1
ð3Þ
s
^ 2i
^w of the regressed MPO values m
^i was then calculated for each
A weighted mean m
plasma sample
wi ¼

k
P
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The absolute and relative replicate variability scores shown in Fig. 8 are,
respectively:
pﬃﬃﬃ
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P
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MPO ELISA. ELISAs on clinical samples were performed in our laboratory
with slight modiﬁcation to the manufacturer’s suggested protocol to minimize
systematic bias between ELISA and MAPS results. The assay volumes and liquid
handling techniques were matched as closely as possible. The standard curve
dilution series was matched to that used in MAPS assays. Plasma and MPO
standard curve samples were loaded and analyzed in triplicate. Plasma samples
of adequate volume to meet the requirements stated by the CHL were shipped
overnight on ice for independent analysis. The CHL assay was performed as
independent triplicates by CLIA-certiﬁed CHL, LLC (Cleveland, OH, USA)
laboratory staff and automated ﬂuid handlers. Raw instrument output was obtained
from the CHL for analysis.

i¼1

i¼1

1
^ 2k þ ^
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s
k
P

where S is bioluminescence signal with asymptote Smax, IC50 is the concentration of
plasma at which S ¼ 12Smax , and H is the Hill coefﬁcient.

^ i wi
m
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m
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This term was combined with individual replicate uncertainty to compute a new
weight and from this a weighted mean accounting for intra- and inter-assay
variance.

ð4Þ
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